Dr. Lerner discovered viral heart damage in CFS patients and recommends Holter monitor test results be part of the diagnostic process.
http://www.immunesupport.com/library/showarticle.cfm?id=8523&T=CFIDS_FM&B1=EM112807C
Valacyclovir treatment in Epstein-Barr virus-subset Chronic Fatigue
Syndrome: Thirty-six months follow-up - Source: In Vivo, Sep-Oct 2007
by AM Lerner, et al.
ImmuneSupport.com
11-23-2007
Background: We hypothesized that subset classification of Epstein-
Barr virus (EBV) in chronic fatigue syndrome (CFS) is required.
At first, a blinded-random placebo-controlled trial of valacyclovir
in EBV CFS subset was performed (Group 1), and this EBV subset was
followed for thirty-six months (Group 2).
Patients were given valacyclovir at 14.3 mg/kg every 6 hours. The
validated Energy Index (EI) point score assessing physical functional
capacity, Holter monitor, multigated (radionuclide) MUGA rest/stress
ventriculographic examination, EBV serum IgM viral capsid antibodies
(VCA), and EBV early antigen diffuse (EA) were followed.
n After six-months, Group 1 CFS patients receiving valacyclovir
experienced an increased mean least square EI point score +1.12 units
(122 kcal/day), while the placebo cohort increased +0.42 EI units (65
kcal/day).
n EI point scores at Group 2 increased progressively. Sinus
tachycardias decreased and abnormal cardiac wall motion improved.
Serum antibody titers to EBV VCA IgM decreased. Patients resumed
normal activities.
Source: In Vivo. 2007 Sep-Oct;21(5):707-13. PMID: 18019402, by Lerner
AM, Beqaj SH, Deeter RG, Fitzgerald JT. Department of Medicine,
William Beaumont Hospital, Royal Oak, MI, USA. [E-mail:
amartinlerner@yahoo.com]
No comments:
Post a Comment